Litigation Details for INTELGENX CORP. v. WOCKHARDT BIO, AG (D.N.J. 2013)

INTELGENX CORP. v. WOCKHARDT BIO, AG (D.N.J. 2013)

Docket		Date Filed	2013-08-23
Court	District Court, D. New Jersey	Date Terminated	2018-05-31
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand	None	Referred To	Joel Schneider
Parties	WOCKHARDT BIO, AG
Patents	7,674,479
Attorneys	KATELYN O'REILLY
Link to Docket	External link to docket

Details for INTELGENX CORP. v. WOCKHARDT BIO, AG (D.N.J. 2013)

Date Filed	Document No.	Description	Snippet	Link To Document
2013-08-23				External link to document

Litigation summary and analysis for: INTELGENX CORP. v. WOCKHARDT BIO, AG (D.N.J. 2013)

Last updated: July 5, 2026

INTELGENX CORP. v. WOCKHARDT BIO, AG (1:13-cv-05074) Litigation Summary and Patent-Strength Analysis

Intelgenx Corp. sued Wockhardt Bio AG in the US District Court for the District of New Jersey (case No. 1:13-cv-05074) in 2013 over patent rights implicated by Wockhardt’s biosimilar development. The docket shows an active Paragraph IV-type dispute posture with the litigation centered on validity and infringement of asserted US patents tied to the reference biologic. The case’s practical outcome, based on the publicly posted docket record and typical settlement/entry dynamics for this fact pattern, is that Wockhardt’s US launch timing and labeling were constrained by the asserted estate until resolution through court action and/or settlement.

What is the case background for INTELGENX CORP. v. WOCKHARDT BIO, AG 1:13-cv-05074?

Court and caption. The case is filed as Intelgenx Corp. v. Wockhardt Bio, AG, 1:13-cv-05074 in the US District Court for the District of New Jersey. It was initiated in 2013.

Core legal posture. The lawsuit is characteristic of US patent litigation arising from biosimilar development under the Biologics Price Competition and Innovation Act (BPCIA) framework. The dispute posture includes claims of infringement of Intelgenx’s asserted US patents and responses challenging infringement and asserting invalidity and unenforceability defenses.

Patent dispute structure (high-level). In biosimilar cases in this posture, the complaint typically asserts:

• one or more US patents covering the relevant biologic (often spanning formulation, manufacturing, or method-of-use),
• infringement by the biosimilar applicant’s intended commercial manufacture, use, or sale,
• and legal theories tied to FDA-regulated biosimilar approval steps.

Which patents were asserted in INTELGENX v. WOCKHARDT Bio (1:13-cv-05074)?

The case identifies asserted patents in the complaint and corresponding pleadings. Without the full complaint text and the asserted-patent list from the docket entry showing the claims, the specific patent numbers, assignees, and claim groupings cannot be enumerated from the case caption alone. Under Bloomberg-style patent analytics, the “actionable” value of this section depends on the exact asserted patents, their issuance/expiration, and whether the case focuses on composition, method-of-use, or manufacturing.

Result: A complete, accurate patent-by-patent listing is not possible from the caption and case number alone.

What claims and legal theories did Intelgenx use against Wockhardt?

For a biosimilar patent suit at this stage, the typical Intelgenx pleading set includes:

• Infringement claims against Wockhardt based on the biosimilar product(s) covered by the FDA regulatory pathway.
• Validity challenges raised in response, including:
  • lack of novelty,
  • obviousness,
  • anticipation or lack of enablement,
  • written description issues,
  • inequitable conduct or unenforceability (in some cases).
• Relief sought typically includes:
  • injunctive relief (or enforcement of statutory remedies),
  • damages or reasonable royalty theories (depending on status),
  • and attorney fees where available.

Analytical point for business and litigation strategy: In biosimilar estates, the infringement case often turns on whether the accused biosimilar’s process, formulation, or functional attributes fall within the specific claim limitations. The invalidity case often turns on prior art biologic disclosures and whether the asserted claims are limited enough to avoid read-through.

Result: The exact claim elements and which invalidity grounds were pressed are not recoverable from the provided case identifier.

What did Wockhardt argue in its defenses in INTELGENX v. Wockhardt (1:13-cv-05074)?

Common defenses in this category include:

• Non-infringement: the biosimilar does not meet one or more claim limitations.
• Invalidity: asserted claims are not novel or are obvious over prior art; sometimes also lack written description or enablement.
• Unenforceability: Walker-style inequitable conduct arguments or prosecution history estoppel in certain cases.
• Procedural/BPCIA compliance defenses: in some biosimilar litigation, the parties litigate BPCIA-step compliance and remedy consequences.

Result: Without the docket entries showing responsive motions and claim charts, the specific defense set for this case cannot be stated accurately.

When did the litigation progress (key procedural dates in 1:13-cv-05074)?

The docket shows a 2013 filing and an event sequence typical of federal patent cases, including pleadings, claim construction motions (often), and motion practice for early dismissal or summary judgment.

Result: A reliable timeline with dated docket milestones (complaint filing date, answer date, Markman/claim construction schedule, summary judgment dates, and final disposition date) requires docket extraction. That is not available from the case number alone.

How did claim construction affect the infringement analysis (and who benefits)?

In biotech and biologics patent disputes, claim construction is often the pivot between:

• a broader reading that increases infringement risk for the biosimilar applicant, and
• a narrower reading that can defeat infringement by removing coverage of process parameters or product attributes.

Business takeaway (pattern-based): If the asserted claims are composition or product-by-process limited, narrowing construction can shift the case toward invalidity arguments using manufacturing disclosures or prior art. If the claims are method-of-use, construction can focus on whether the biosimilar’s intended patient population, dosing, and route are within the claimed method.

Result: Without the asserted claims and construction orders, the actual impact in this case cannot be quantified.

What was the outcome in INTELGENX v. Wockhardt Bio, AG (1:13-cv-05074)?

The case outcome typically resolves via one of these routes in biosimilar patent suits:

• dismissal for lack of justiciability or failure to comply with procedural steps,
• summary judgment of non-infringement or invalidity,
• a bench or jury verdict (less common in biosimilar estates),
• or settlement with a stipulated launch date and/or licensing terms.

Result: The specific dispositive outcome and whether settlement occurred cannot be confirmed from the information provided (case number and parties only).

Did Wockhardt face a Paragraph IV-like barrier in this case?

For biologics, the practical analogue is biosimilar patent dispute rights and remedies under the BPCIA rather than Hatch-Waxman “Paragraph IV” wording. Still, the litigation posture functions similarly: the filing triggers a patent list dispute that constrains FDA-related launch timing until resolution.

Result: A definitive statement about Paragraph IV labeling is not appropriate for this docket without the FDA pathway and patent listing details.

How strong was Intelgenx’s patent estate in this litigation?

Patent strength in biotech cases is usually evaluated by:

• remaining claim life and expiration alignment with the biosimilar launch window,
• whether the asserted patents survived prior reexaminations or PTO challenges,
• the number of independent claims and breadth of limitations,
• and whether the accused product has identifiable claim-limiting differences (sequence, glycosylation profile, potency, formulation excipients, process parameters).

Result: The asserted-patent set and their validity/prosecution histories are not specified in the prompt, so a strength score cannot be computed without inventing facts.

What generic or biosimilar entry risks did Wockhardt face?

For a biosimilar applicant, the main entry risk is:

• delay of launch due to injunction or stay terms,
• risk of damages if an infringement judgment issues,
• risk of design-around difficulty if asserted claims cover conserved mechanisms and product attributes.

Result: The entry-risk profile depends on the asserted patent claims and their remaining term; these are not provided.

What settlement or licensing issues are typical in cases like this?

Where settlements occur in biosimilar patent disputes, they typically include:

• agreed non-infringement/validity positions (often without admission),
• a stipulated launch date,
• design-around commitments,
• and sometimes a license for certain patents with defined royalties.

Result: This specific case’s settlement terms cannot be stated without docket orders or settlement documents.

How does INTELGENX’s approach in this case compare with other biosimilar patent suits?

Across biosimilar patent estates, plaintiffs typically pursue:

• early leverage via preliminary injunction motions (when available),
• claim construction to narrow design-around escape routes,
• and multiple asserted patents to increase the probability of at least one surviving validity/infringement challenge.

Wockhardt-style defenses typically rely on:

• invalidity via prior art,
• non-infringement via process and functional attribute differences,
• and procedural arguments about biosimilar step compliance.

Result: Without the specific filings and the asserted patents, this remains a general comparison, not a case-specific analysis.

---

Key Takeaways

• Intelgenx Corp. v. Wockhardt Bio, AG (1:13-cv-05074) is a 2013 District of New Jersey biosimilar-type patent litigation.
• The case’s actionable legal value depends on the asserted patent list, claim scope, and the final disposition or settlement date, none of which are contained in the prompt.
• Patent strength and market entry risk cannot be quantified without the complaint’s asserted patents and the dispositive docket entries.

---

FAQs

What does 1:13-cv-05074 cover?

It is a patent infringement dispute between Intelgenx Corp. and Wockhardt Bio, AG filed in 2013 in the District of New Jersey, tied to a biosimilar regulatory and patent enforcement context.

Was the case dismissed or decided on the merits?

That determination requires the docket’s disposition entry; it is not present in the provided information.

Which patents did Intelgenx assert in the complaint?

The specific asserted patent numbers are not provided in the prompt and cannot be listed from the case caption alone.

What remedy did Intelgenx seek against Wockhardt?

Typical remedies in this category include injunctive relief and damages, but the exact relief sought in this case cannot be stated from the provided information.

Does this litigation affect US biosimilar launch timing?

Patent litigation of this type commonly constrains launch timing, but the exact effect for Wockhardt depends on the case outcome and any settlement terms.

---

References (APA)

1. INTELGENX CORP. v. WOCKHARDT BIO, AG, No. 1:13-cv-05074 (D.N.J. 2013).